LMY-920 for Treatment of Relapsed or Refractory Myeloma
Condition(s):Multiple Myeloma, Refractory; Multiple Myeloma in RelapseLast Updated:March 15, 2024Recruiting
Hide Studies Not Open or Pending
Condition(s):Multiple Myeloma, Refractory; Multiple Myeloma in RelapseLast Updated:March 15, 2024Recruiting
Condition(s):Multiple Myeloma in Relapse; Refractory Multiple MyelomaLast Updated:January 31, 2024Active, not recruiting
Condition(s):Multiple Myeloma in Relapse; Refractory Multiple MyelomaLast Updated:January 31, 2024Active, not recruiting
Condition(s):Multiple Myeloma; Multiple Myeloma in Relapse; Multiple Myeloma, RefractoryLast Updated:July 20, 2023Not yet recruiting
Condition(s):Multiple Myeloma; Allogeneic Stem Cell TransplantationLast Updated:March 19, 2024Not yet recruiting
Condition(s):Multiple Myeloma in Relapse; Multiple Myeloma, RefractoryLast Updated:June 18, 2019Completed
Condition(s):Multiple Myeloma in Relapse; Multiple Myeloma ProgressionLast Updated:October 16, 2018Unknown status
Condition(s):Multiple Myeloma in Relapse; Multiple MyelomaLast Updated:August 28, 2017No longer available
Condition(s):Multiple Myeloma; Multiple Myeloma in RelapseLast Updated:February 23, 2018Completed
Condition(s):Multiple Myeloma in Relapse; Multiple MyelomaLast Updated:February 12, 2016Withdrawn
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.